Airship AI Holdings, Inc.

8210 154th Ave NE

Redmond, WA 98052

 

April 10, 2024

 

VIA EDGAR

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Alexandra Barone

 

Re:

Airship AI Holdings, Inc.

Registration Statement on Form S-1

Filed February 7, 2024

File No. 333-276932

 

Dear Ms. Barone:

 

Airship AI Holdings, Inc. (the “Company”, “we”, “us” or “our”) hereby transmits our response to the comment letter received by us from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”), dated February 21, 2024, regarding the Company’s Registration Statement on Form S-1 (the “Registration Statement”) previously filed with the Commission on February 7, 2024.

 

For the Staff’s convenience, we have repeated below the Staff’s comments in bold, and have followed each comment with the Company’s response. Changes to the Registration Statement based on the Staff’s comments are reflected in Amendment No. 2 to the Registration Statement (“Amendment No. 2”) which is being submitted to the Commission concurrently with the submission of this letter.

 

Registration Statement on Form S-1

 

Cover Page

 

1.

For each of the securities being registered for resale, disclose the price that the selling securityholders paid for such securities.

 

RESPONSE: The Company has revised the disclosure on the cover page and page 79 of Amendment No. 2 in response to the Staff’s comment.

 

Risk Factors, page 8

 

2.

In your risk factors and MD&A section, disclose the exercise prices of the warrants compared to the market price of the underlying securities and the likelihood that warrant holders will not exercise their warrants. Disclose that cash proceeds associated with the exercises of the warrants are dependent on the stock price. As applicable, describe the impact on your liquidity and update the discussion on the ability of your company to fund your operations on a prospective basis with your current cash on hand.

 

RESPONSE: The Company has revised the disclosure on pages 28 and 38 of Amendment No. 2 in response to the Staff’s comment.

 

 

1

 

 

3.

Include an additional risk factor highlighting the negative pressure potential sales of shares pursuant to this registration statement could have on the public trading price of the common stock. To illustrate this risk, disclose the purchase price of the securities being registered for resale and the percentage that these shares currently represent of the total number of shares outstanding. Also disclose that even though the current trading price is significantly below the SPAC IPO price, certain private investors have an incentive to sell because they will still profit on sales because of the lower price that they purchased their shares than the public investors.

 

RESPONSE: The Company has revised the risk factor disclosure on page 28 of Amendment No. 2 in response to the Staff’s comment.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations Company Overview, page 48

 

4.

Please expand your discussion here to reflect the fact that this offering involves the potential sale of a substantial portion of shares for resale and discuss how such sales could impact the market price of the company’s common stock. Your discussion should highlight the fact that Derek Xu and Victor Huang and their affiliates, beneficial owners of 40.5% and 30% of your outstanding shares, respectively, will be able to sell all of their shares for so long as the registration statement of which this prospectus forms a part is available for use.

 

RESPONSE: The Company has revised the disclosure on page 42 of Amendment No. 2 in response to the Staff’s comment.

 

Liquidity and Capital Resources as of September 30, 2023 and 2022, page 54

 

5.

In light of the significant number of redemptions and the unlikelihood that the company will receive significant proceeds from exercises of the warrants because of the disparity between the exercise price of the warrants and the current trading price of the common stock, expand your discussion of capital resources to address any changes in the company’s liquidity position since the Business Combination. For example, disclose the total number of public shares that were redeemed since the SPAC IPO and in connection with the Business Combination and the resulting amount of funds you received from the trust account. Disclose the amount of debt and other securities issued, net proceeds received, and fees paid or payable to finance the company and its obligations in connection with and following the Business Combination. If the company is likely to have to seek additional capital, discuss the effect of this offering on the company’s ability to raise additional capital.

 

RESPONSE: The Company has revised the disclosure on page 38 of Amendment No. 2 in response to the Staff’s comment.

 

 

2

 

 

General

 

6.

Revise your prospectus to disclose the price that each selling securityholder paid for the securities being registered for resale. Highlight any differences in the current trading price, the prices that the selling securityholders acquired their securities, and the price that the public securityholders acquired their shares and warrants. Disclose that while the selling securityholders may experience a positive rate of return based on the current trading price, the public securityholders may not experience a similar rate of return on the securities they purchased due to differences in the purchase prices and the current trading price. Please also disclose the potential profit the selling securityholders will earn based on the current trading price. Lastly, please include appropriate risk factor disclosure.

 

RESPONSE: The Company has revised the disclosure on the cover page, page 28 and page 79 of Amendment No. 2 in response to the Staff’s comment.

 

***

 

We thank the Staff in advance for its review of the foregoing and Amendment No. 2. If you have further comments, we ask that you forward them by electronic mail to our counsel, David J. Levine, Esq., at dlevine@loeb.com or by telephone at (212) 407-4923.

 

 

Very truly yours,

 

 

 

 

 

/s/ Victor Huang

 

 

Victor Huang,

Chief Executive Officer

 

 

 

3